Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Nov 2, 2026 is 586.54 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 917.05 M CNY — a change of -36.04% (lower).

EBITDA

586.54 MCNY

YoY

-36.04%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pacific Shuanglin Bio-pharmacy Co is 2025 586.54 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pacific Shuanglin Bio-pharmacy Co was 2024 917.05 M CNY. It decreases by -36.04% lower compared to the previous year.

The Pacific Shuanglin Bio-pharmacy Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
144.89 M CNY
Jan 1, 2019
213.77 M CNY
Jan 1, 2020
242.10 M CNY
Jan 1, 2021
496.88 M CNY
Jan 1, 2022
702.83 M CNY
Jan 1, 2023
738.69 M CNY
Jan 1, 2024
917.05 M CNY
Jan 1, 2025
586.54 M CNY
The Pacific Shuanglin Bio-pharmacy Co EBITDA history
YEAREBITDAYoY
586.54 MCNY-36.04%
917.05 MCNY+24.15%
738.69 MCNY+5.10%
702.83 MCNY+41.45%
496.88 MCNY+105.24%
242.10 MCNY+13.25%
213.77 MCNY+47.54%
144.89 MCNY+31.79%
109.94 MCNY+4.63%
105.07 MCNY+11.64%
94.12 MCNY-22.51%
121.45 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pacific Shuanglin Bio-pharmacy Co is 586.54 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pacific Shuanglin Bio-pharmacy Co changed from 917.05 M CNY to 586.54 M CNY, representing a -36.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Pacific Shuanglin Bio-pharmacy Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Pacific Shuanglin Bio-pharmacy Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co